Article
Design of proteolytically stable RI-anchoring disruptor peptidomimetics for <i>in vivo</i> studies of anchored type I protein kinase A-mediated signalling
3 Sept 2009
Abstract excerpt
We have reported previously the design of a RIAD (RI-anchoring disruptor) peptide that specifically displaces PKA (protein kinase A) type I from the AKAP (A-kinase-anchoring protein) ezrin, which is present in the immunological synapse of T-cells. This increases immune reactivity by reducing the threshold for activation and may prove a feasible approach for improving immune function in patients with cAMP-mediated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
